Oncolytics Biotech®已与美国食品药品监督管理局（FDA）就其用于二线治疗Ras突变型微卫星稳定（MSS）结直肠癌的注册路径达成一致意见。这一进展标志着该公司在推进这一适应症候选药物开发过程中迈出了关键一步。通过与监管机构的积极沟通，公司现已明确后续临床开发及上市申请所需的关键要素。
Oncolytics Biotech®已与美国食品药品监督管理局（FDA）就其用于二线治疗Ras突变型微卫星稳定（MSS）结直肠癌的注册路径达成一致意见。这一进展标志着该公司在推进这一适应症候选药物开发过程中迈出了关键一步。通过与监管机构的积极沟通，公司现已明确后续临床开发及上市申请所需的关键要素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.